Nasus Pharma Ltd

Nasus Pharma Ltd (NSRX) priced its initial public offering on Aug 14, 2025 at $8.00 per share, raising $10M, and listed on NYSE American. At the IPO price its market capitalization was about $72.5M. Laidlaw was lead-left underwriter, joined by Craft Capital. Sullivan & Worcester advised the company and Sichenzia Ross Ference Carmel advised the underwriters.

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company developing intranasal drugs for emergency medical conditions. It is developing a powder-based intranasal technology with a product portfolio addressing acute medical conditions and public health threats.

Status

IPO

Ticker

NSRX

Exchange

NYSE American

Priced

Aug 14, 2025

IPO price

$8.00

Raised

$10M

Market cap at IPO price

$72.5M

First filed

Jul 9, 2025

Underwriters

Laidlaw and Craft Capital

Company counsel

Sullivan & Worcester

Underwriters' counsel

Sichenzia Ross Ference Carmel

Sector

Biotech & pharma

Country / state

Israel

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.